quinoxalines has been researched along with Leukemia, Lymphocytic, Chronic, B-Cell in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Bertoni, F; Lupia, A; Stathis, A; Tarantelli, C | 1 |
| Ailawadhi, S; Arnason, J; Brown, JR; Doorduijn, JK; Egile, C; Gabrail, NY; Ganguly, S; Gao, L; Hamadani, M; Hayslip, J; Janssens, A; Kasar, S; Kater, AP; Kersten, MJ; Lager, JJ; Millenson, M; Offner, F; Ottmann, O; Tilly, H; Wagner-Johnston, N; Wu, B | 1 |
| Naessens, E; Pede, V; Philippé, J; Rombout, A; Vanderstraeten, H; Verhasselt, B; Vermeire, J | 1 |
| Abrisqueta, P; Awan, FT; Brown, JR; Davids, MS; Egile, C; Jiang, J; Kasar, SN; Lager, J; Rodon, J | 1 |
| Baars, JW; de Rooij, MF; Egile, C; Eldering, E; Jansen, MH; Kater, AP; Kersten, MJ; Kuijpers, TW; Kuil, A; Spaargaren, M; Ter Burg, J; Thijssen, R; van Bochove, GG; van Oers, MH; Virone-Oddos, A | 1 |
| Alonso, R; Campo, E; Colomer, D; López-Guerra, M; Montserrat, E; Pérez-Galán, P; Roué, G; Villamor, N | 1 |
| Coll-Mulet, L; Cosialls, AM; de Frias, M; de la Banda, E; Gil, J; González-Gironès, DM; Iglesias-Serret, D; Pons, G; Santidrián, AF | 1 |
| Al-Katib, AM; Mensah-Osman, EJ; Mohammad, RM; Osman, NI; Wu, HY | 1 |
1 review(s) available for quinoxalines and Leukemia, Lymphocytic, Chronic, B-Cell
| Article | Year |
|---|---|
Is There a Role for Dual PI3K/mTOR Inhibitors for Patients Affected with Lymphoma?
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Chromones; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Molecular Targeted Therapy; Oligopeptides; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinoxalines; Signal Transduction; Sulfonamides; TOR Serine-Threonine Kinases | 2020 |
2 trial(s) available for quinoxalines and Leukemia, Lymphocytic, Chronic, B-Cell
| Article | Year |
|---|---|
Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial.
Topics: Cohort Studies; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Quinoxalines; Sulfonamides | 2018 |
Phase I Trial of the Pan-PI3K Inhibitor Pilaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory Lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cohort Studies; Female; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Male; Middle Aged; Neoplasm Recurrence, Local; Phosphoinositide-3 Kinase Inhibitors; Quinoxalines; Sulfonamides | 2015 |
5 other study(ies) available for quinoxalines and Leukemia, Lymphocytic, Chronic, B-Cell
| Article | Year |
|---|---|
Expression of ZAP70 in chronic lymphocytic leukaemia activates NF-κB signalling.
Topics: Adult; Aged; Calcium Signaling; Electroporation; Female; Gene Expression Regulation, Leukemic; Humans; I-kappa B Kinase; Imidazoles; Immunoglobulin Heavy Chains; Immunoglobulin M; Immunoglobulin Variable Region; Interleukin-1beta; Interleukin-6; Interleukin-8; Interleukins; Jurkat Cells; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Proteins; NF-kappa B; Prognosis; Quinoxalines; Receptors, Antigen, B-Cell; Recombinant Fusion Proteins; RNA, Messenger; Transcription Factor RelA; Transcriptome; Tumor Cells, Cultured; ZAP-70 Protein-Tyrosine Kinase | 2013 |
The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells.
Topics: Adolescent; Adult; CD40 Antigens; Cell Adhesion; Cell Proliferation; Cell Survival; Cytokines; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Phosphoinositide-3 Kinase Inhibitors; Purines; Quinazolinones; Quinoxalines; Sulfonamides; T-Lymphocytes; TOR Serine-Threonine Kinases | 2016 |
p65 activity and ZAP-70 status predict the sensitivity of chronic lymphocytic leukemia cells to the selective IkappaB kinase inhibitor BMS-345541.
Topics: Adult; Aged; Aged, 80 and over; Apoptosis; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; I-kappa B Kinase; Imidazoles; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; NF-kappa B; Quinoxalines; Transcription Factor RelA; ZAP-70 Protein-Tyrosine Kinase | 2009 |
Akt inhibitors induce apoptosis in chronic lymphocytic leukemia cells.
Topics: Aged; Aged, 80 and over; Apoptosis; Apoptosis Regulatory Proteins; B-Lymphocytes; Benzylamines; Blotting, Western; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Female; Humans; Indazoles; Indoles; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Male; Middle Aged; Myeloid Cell Leukemia Sequence 1 Protein; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Quinoxalines; Reverse Transcriptase Polymerase Chain Reaction; T-Lymphocytes; Tumor Suppressor Protein p53 | 2009 |
2-[4-(7-chloro-2-quinoxalinyloxyphenoxy]-propionic acid (XK469), an inhibitor of topoisomerase (Topo) IIbeta, up-regulates Topo IIalpha and enhances Topo IIalpha-mediated cytotoxicity.
Topics: Antigens, Neoplasm; Blotting, Western; Culture Media, Serum-Free; DNA; DNA Topoisomerases, Type II; DNA-Binding Proteins; Enzyme Inhibitors; Etoposide; Humans; Immunohistochemistry; Leukemia, Lymphocytic, Chronic, B-Cell; Microscopy, Confocal; Microscopy, Fluorescence; Neoplasm Transplantation; Protein Isoforms; Quinoxalines; Time Factors; Tumor Cells, Cultured; Up-Regulation; Waldenstrom Macroglobulinemia | 2002 |